Stem Cell Therapeutics Corp.

Development and commercialisation of therapeutics that stimulate adult stem cells

Primarily, Stem Cell Therapies was a subsdiary of Transition Therapeutics, Inc. In October 2004, Stem Cell Therapies was sold to Neurogenesis Biotech Corp. to strengthen Neurogenesis’ intellectual property portfolio, and Neurogenesis changed its name to Stem Cell Therapeutics Corp. SCT is traded on the Toronto Stock Exchange (TSX-V) under the ticker symbol SSS.

Alan Moore Dr., President and CEO
Mark Wayne, CFO
Brett Schönekess, Vice President of Operations
Alan Davidoff, Dr., Vice President of Product Development

Jean-Paul Castaigne, Dr.
Mark Wayne
James M. DeMesa, Dr.
Ian Brown

Myron Ginsberg, MD, Prof.
Joshua Hare, MD, Prof.
Craig Pratt, MD, Prof.
Samuel Weiss, PhD, Prof.

Suite 1000, 1520 4th St SW
Calgary, AB, T2R 1H5
Canada
Phone: +1-403-245-5495
Fax: +1-403-245-5411

The company has developed a technology platform and intellectual property to selectively induce a patient’s own stem cells to proliferate in the brain.

Stem Cells Therapies’ lead therapeutic product, NTx™-265, has been demonstrated to increase the number of adult stem cells when applied to experimental animals. This product is destined for the treatment of patients suffering from stroke, Huntington’s
disease, Alzheimer’s and other neurodegenerative conditions.

In cooperation with Medicon, Denmark, SCT conduct its first Phase I clinical trial to test NTx™-265 for the treatment of stroke.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.